Literature DB >> 2909373

Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein.

S Fukayama1, A H Tashjian.   

Abstract

We have investigated the actions of 17 beta-estradiol (E2) on the production of cAMP stimulated by synthetic human PTH [hPTH-(1-34)], synthetic hPTH-related protein [hPTHrP-(1-34)], and vasoactive intestinal peptide (VIP) in human (SaOS-2) and rat (ROS 17/2.8) osteoblast-like osteosarcoma cells. In SaOS-2 cells, hPTH-(1-34) (2.5 nM), hPTHrP-(1-34) (2.5 nM), and VIP (10-100 nM) stimulated the accumulation of cAMP markedly (greater than 20- to 30-fold in 1 h). Cells were preincubated in serum-free medium for 4-24 h, then in the absence or presence of E2 for 4 h before a 1-h stimulation with peptide hormone in the absence of E2. In SaOS-2 cells, pretreatment with E2 (10(-12)-10(-8) M) for 4 h inhibited by up to 50% the accumulation of cAMP stimulated by hPTH-(1-34) or hPTHrP-(1-34), but E2 had no inhibitory effect on VIP action. 17 alpha-Estradiol had no inhibitory action on hPTH- or hPTHrP-stimulated accumulation of cAMP at concentrations as high as 10(-8) M. Additional evidence against a nonspecific effect of E2 was the total lack of inhibition of cAMP accumulation stimulated by hPTH-(1-34) or hPTHrP-(1-34) in ROS 17/2.8 cells at concentrations of E2 up to 10(-6) M. We conclude that E2 can act directly and rapidly in human osteoblast-like cells to modulate selectively the ability of hPTH and hPTHrP to enhance the production of cAMP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909373     DOI: 10.1210/endo-124-1-397

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

1.  Androgen receptors in osteoblast-like cell lines.

Authors:  E S Orwoll; L Stribrska; E E Ramsey; E J Keenan
Journal:  Calcif Tissue Int       Date:  1991-09       Impact factor: 4.333

2.  Protein kinase A-dependent inhibition of alkaline phosphatase release by SaOS-2 human osteoblastic cells: studies in new mutant cell lines that express a cyclic AMP-resistant phenotype.

Authors:  S Fukayama; A K Kearns; R M Skurat; A H Tashjian; F R Bringhurst
Journal:  Cell Regul       Date:  1991-11

3.  Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats.

Authors:  T Takano-Yamamoto; G A Rodan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 4.  That oestrogen replacement for osteoporosis prevention should no longer be a bone of contention.

Authors:  T G Palferman
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

5.  Bone endothelial cells as estrogen targets.

Authors:  M L Brandi; C Crescioli; A Tanini; U Frediani; D Agnusdei; C Gennari
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

6.  Functional estrogen receptors in a human preosteoclastic cell line.

Authors:  G Fiorelli; F Gori; M Petilli; A Tanini; S Benvenuti; M Serio; P Bernabei; M L Brandi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 7.  Androgens and bone.

Authors:  Bart L Clarke; Sundeep Khosla
Journal:  Steroids       Date:  2008-10-17       Impact factor: 2.668

8.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Authors:  G Girasole; R L Jilka; G Passeri; S Boswell; G Boder; D C Williams; S C Manolagas
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

9.  Estrogen receptors and biologic response in rat parathyroid tissue and C cells.

Authors:  T Naveh-Many; G Almogi; N Livni; J Silver
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

10.  Serum triiodothyronine, bone turnover, and bone mass changes in euthyroid pre- and postmenopausal women.

Authors:  A Schoutens; E Laurent; E Markowicz; J Lisart; V De Maertelaer
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.